SB77 establishes a state program focused on ibogaine research and clinical development in Kentucky. It creates an ibogaine research and intellectual property fund in the State Treasury, administered by the Department of Agriculture, to support a public-private partnership with a drug developer conducting multistate clinical trials aimed at obtaining FDA approval for ibogaine. The bill defines ibogaine broadly, authorizes the fund to receive appropriations and other public or private money, and allows unspent balances and investment earnings to carry forward.
The bill requires any participating drug developer to submit detailed trial plans, FDA approval strategies, participant protocols, financial disclosures, and proof of an existing multistate agreement. The department must negotiate a contract requiring the developer to match the Commonwealth’s investment, use in-state clinicians, facilities, and participants for the Kentucky trials, and develop a plan for broad post-approval access, including priority access for Kentucky residents, payer coverage, access for uninsured and low-income patients, and provider training. The bill also gives Kentucky an economic interest in intellectual property generated through the trials and directs commercialization proceeds back into the fund.
SB77 further requires quarterly progress and financial reports from the developer and an annual report to the Legislative Research Commission and the Interim Joint Committee on Health Services. It limits future expenditures from commercialization proceeds to programs or research benefiting at-risk populations with conditions potentially treatable with ibogaine, including opioid use disorder, PTSD, traumatic brain injury, and other neurological or mental health disorders. The bill includes an emergency clause, making it effective immediately upon enactment.
The bill’s fiscal structure is significant: it transfers $21 million per fiscal year from the opioid abatement trust fund for the 2026-2028 biennium into the new ibogaine fund. In practical terms, it redirects opioid settlement resources toward a targeted research and development initiative, while also creating a framework for the Commonwealth to share in any resulting intellectual property value.
The overall sentiment reflected in the vote history suggests substantial support, but not unanimity. The bill passed both chambers and later survived veto override votes in both the House and Senate, indicating enough legislative backing to enact it despite executive opposition. The main point of contention appears to be the use of opioid abatement funds and the policy choice to invest public money in ibogaine, a psychogenic compound associated with substance use and mental health treatment research, rather than in more established programs or treatments.
SB77 adds new sections to KRS Chapter 218A to create a state-administered ibogaine research and intellectual property fund and authorize the Department of Agriculture to enter into public-private research partnerships. It also transfers $21 million per fiscal year from the opioid abatement trust fund for the 2026-2028 biennium into the new fund, making those amounts available for ibogaine clinical trials, related research, and later-benefit programs. The bill affects state fiscal law, opioid settlement fund usage, public procurement/contracting for research, and the handling of intellectual property proceeds tied to state-supported drug development.
The bill appears to have had generally favorable legislative support, as shown by strong passage margins in both chambers and successful veto overrides. That said, the override votes also indicate that the measure was controversial enough to draw executive resistance and a meaningful minority of opposition in each chamber. The overall sentiment in the legislature seems to have been that the bill represented a promising, innovative investment in addiction and mental health research, while opponents likely questioned the prudence of funding ibogaine research with opioid abatement dollars.
The principal controversy is the diversion of opioid abatement trust fund money to ibogaine research, which some lawmakers likely viewed as an unproven or unconventional use of settlement funds. Another likely point of dispute is the bill’s reliance on a public-private partnership with a drug developer and the state’s role in negotiating intellectual property rights and commercialization proceeds. Supporters appear focused on potential treatment breakthroughs for opioid use disorder and related conditions, while critics likely raised concerns about scientific uncertainty, fiscal risk, and whether the state should commit substantial funds to a compound that still requires FDA approval.